Filing Flows › 4D Molecular Therapeutics (FDMT) › Q2 2026
4D Molecular Therapeutics (FDMT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
4D Molecular Therapeutics (FDMT) reported revenue of $3.8M for the second quarter 2026 (Q2 2026), up 252-fold from a year earlier and +24% from the quarter before.
4D Molecular Therapeutics, Q2 2026: revenue $3.8M (252× year over year), net loss $72.9M, operating cash flow −$70.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.8M | +24% | 252× |
| Operating profit | −$77.0M | — | — |
| Net earnings | −$72.9M | — | — |
| Operating cash flow | −$70.0M | — | — |
What changed
Revenue was $3.8M in Q2 2026, up 25107% year over year and up 24% from the previous quarter.
Operating costs exceeded revenue by $77.0M, an operating margin of -2037.2%. Total costs grew 36% against revenue growth of 25107%. The fastest-growing cost line was Research & development (+42%). The quarter ended with a net loss of $72.9M, wider than the previous quarter's $68.8M loss.
Operating cash flow was −$70.0M. Non-cash charges added back $1.3M of depreciation and amortization and $5.9M of share-based compensation. Working capital and other items used $4.2M.
Questions
What was 4D Molecular Therapeutics' revenue in the second quarter 2026?
4D Molecular Therapeutics (FDMT) reported revenue of $3.8M for the second quarter 2026 (Q2 2026), up 252-fold from a year earlier and +24% from the quarter before.